Last reviewed · How we verify
Spironolactone Oral Tablet
At a glance
| Generic name | Spironolactone Oral Tablet |
|---|---|
| Also known as | Spironolactone, Carospir® |
| Sponsor | Qifu Li |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Spironolactone Improved Children With Gene Mutations Related to NCOR (PHASE2, PHASE3)
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (PHASE3)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories (PHASE2)
- Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (PHASE3)
- Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (PHASE3)
- Drug-Drug Interaction Study in Trans Women Living With HIV (PHASE4)
- Spironolactone for Hidradenitis Suppurativa (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spironolactone Oral Tablet CI brief — competitive landscape report
- Spironolactone Oral Tablet updates RSS · CI watch RSS
- Qifu Li portfolio CI